Following on from information provided to NICE by the company in March 2021, the appraisal of Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3856 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Following on from information provided to NICE by the company in March 2021, the appraisal of Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2021, the appraisal of Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 30 March 2021 | For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 30 March 2021 | Suspended. Topic is suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual